The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/24394

Please be advised that this information was generated on 2019-04-16 and may be subject to change.
The role of inhaled corticosteroids (ICS) in the long-term management of COPD is still unclear. Therefore, we performed a meta-analysis of the three-year studies published on this subject (Kerstjens et al: N Engl J Med 1992; 327: 1413-9, Derouen et al: Am J Respir Crit Care 1995: 151: A463, Derouen et al: Chest 1996; 109: 156-62. Patients with "asthmatic features" were excluded by analyzing the original data. The effect on FEV1 was assessed by a multiple repeated measurement technique in which time and drug effects were investigated. 95 (of the original number of 140) Patients treated with ICS (81 with 1500 ¿g beclomethasone, 6 with 1650 ¿g budesonide, and 8 with 800 ¿g beclomethasone) were included. 88 Patients treated with placebo were included (of the initially 144 patients). No baseline differences were observed (mean age 61 years, mean FEV1 = 45%pred.). Worsening of the disease was the drop-out reason in 4 patients of the ICS group vs. 9 of the placebo group (p = 0.11). The estimated two-year effect on the ICS group versus placebo, the postbronchodilator FEV1, showed a difference of +0.083L (95% c.i. = +0.003L to +0.163L). In conclusion, this meta-analysis showed beneficial long-term effects of ICS on the FEV1 in patients with a clear diagnosis of COPD.

2510 When to perform arterial blood gases (ABG) in stable chronic obstructive pulmonary disease (COPD)?

N. Roche, B. Herer, T.C. Chinët, S. Labrunère, G.J. Huchon. Université de Paris Hôpital Descartes, Service de Pneumologie, Hôpital Ambroise Paré. F-92104 Boulogne, France

In patients with stable COPD, there is no agreement on the FEV1 threshold above which ABG are unnecessary to identify patients who would require supplemental O2 therapy. The American Thoracic Society and French guidelines recommend to perform ABG when FEV1 is less than 50% predicted, whereas the European Respiratory Society recommends to perform ABG when FEV1 is less than 70% predicted. Several studies have shown a poor correlation between spirometry and PaO2. We studied data from 60 stable COPD patients to determine the baseline FEV1 threshold above which patients exhibit no severe hypoxemia (as defined by PaO2 < 60 mmHg). Spirometry and ABG were performed on the same day in each patient, at least three weeks after the last exacerbation.

![FEV1 vs PaO2](image.png)

There was a weak but significant correlation between FEV1 and PaO2 (r² = 0.13, p = 0.005). The correlation between FEV1 and PaCO2 was stronger (r² = 0.25, p = 0.00005). In all patients whose FEV1 was >55% predicted, PaO2 was >60 mmHg. These data suggest that 55% would be an acceptable FEV1 threshold above which measurement of ABG is not necessary in stable COPD patients.

2511 Survey of prescription of long term oxygen therapy outside guidelines

A. Taydard, D. Veule, E. Chailleux, J.C. Cardinaud, Groupe d’Etude Observatoire CMTS, ANTADIR, Bil St Michel, 75006 Paris, France

Guidelines for the prescription of long term oxygen therapy (LTOT) have been published but many surveys have found a large proportion of patients prescribed LTOT to have arterial oxygen pressure above guideline thresholds. We have surveyed prescribers of LTOT to patients enrolled in the ANTADIR (French National Respiratory homecare network) Observatory. 2081 questionnaires were sent to prescribers identified by 20 regional associations asking if they ever prescribed LTOT to stable COPD patients with PaO2 > 60 mmHg and asking them to mark any of 9 suggested situations or "other reason" for such prescription, 654 replies have been received. The mean age of doctors was 43.5 ± 7 yr. and 81% were respiratory physicians. 117/644 (17.8%) had never prescribed LTOT at PaO2 ≥ 60 mmHg. The remaining 537 marked a median of three options. 154 marked 5 options or more. The commonest motives for prescription outside guidelines were: "nocturnal desaturation" (38%), "pulmonary hypertension" (33%), and "recent clinical right heart failure" (34%). 172 (31%) doctors ticked at least these three situations together. In contrast the options of prescription in "response to demand by the patient" or "family" were only chosen 40 times, 309 prescribed for "effort desaturation", 215 for "dyspnea", 139 for "repeat hospitalization", 127 for "poly-cytarhymia". We conclude that physicians prescribe LTOT outside guidelines for objective rather than subjective reasons of perceived severity of disease and trials of efficacy of LTOT in these circumstances are required.

2512 Nocturnal oxyhemoglobin desaturation (NOD) as predictor of long-term oxygen therapy (LTOT)

M. Rizzi, A. Bellemo1, M. Greco, A. Andreoli, M. Bambergia, M. Sergi, Servizio di Pneumologia Respiratoria Ospedale L. Sacco Milano; 1Servizio di Pneumologia Respiratoria e Bronconeumologia Ospedale Rho-Passirana, Italy

NOD often occurs among COPD patients with daytime PaO2 < 60 mmHg, and our aim was to evaluate the outcome of these subjects.

Methods: 210 COPD were observed from January 1991 to December 1995 with chronic severe hypoxemia (PaO2 50.8 ± 6.5 mmHg) treated with LTOT (LTOT subjects) and 34 with NOD, assessed by 15% of the recorded time with SaO2 < 90 and diurnal PaO2 64 ± 7 mmHg (NOD subjects).

Results: We compared age and PaO2, of LTOT subjects and NOD subjects (Student’s t test, level of significance p < 0.05). NOD subjects compared to LTOT subjects were younger (64 ± 3 vs 70 ± 0.4 yrs; p = 0.05), had FEV1 higher (50 ± 7.0 vs 36 ± 6.6 ± pred p < 0.0001). During follow-up, daytime PaO2 in 103/4 NOD subjects fell to values that required LTOT: these patients showed, compared to other 24 NOD subjects, PaO2 significantly reduced (42 ± 7 versus 56.6 ± 2%, p < 0.0001) and greater PaCO2 (58 ± 15 versus 35 ± 13, p < 0.0001) while PaCO2 slightly different (61.3 ± 4.6 versus NOD). Conclusions: We speculate that our 34 NOD patients are a subgroup, with an earlier stage of their disease, leading progressively to severe chronic hypoxemia: bronchial obstruction and Pack Years are the risk factors for the worsening diurnal PaO2.